Tripodi v. Johnson & Johnson

877 F. Supp. 233, 1995 U.S. Dist. LEXIS 1959, 1995 WL 75307
CourtDistrict Court, D. New Jersey
DecidedJanuary 26, 1995
DocketCiv. A. 90-1926 (DRD)
StatusPublished
Cited by12 cases

This text of 877 F. Supp. 233 (Tripodi v. Johnson & Johnson) is published on Counsel Stack Legal Research, covering District Court, D. New Jersey primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Tripodi v. Johnson & Johnson, 877 F. Supp. 233, 1995 U.S. Dist. LEXIS 1959, 1995 WL 75307 (D.N.J. 1995).

Opinion

OPINION

DEBEVOISE, Senior District Judge.

Plaintiff, Dr. Daniel Tripodi, brought this suit for wrongful discharge arising out of his employment at defendant, Therakos, Inc. (“Therakos”) from January 1, 1988 to July 24, 1989. In his First Amended Complaint, plaintiff advanced many causes of action, but all except a “Woolley ” claim were dismissed prior to trial on a summary judgment motion. The Woolley claim was tried before a jury which returned a verdict in favor of plaintiff, awarding him damages in the amount of $434,000 1 . Therakos now moves for judgntent notwithstanding the verdict, or, alternatively, a new trial. For the reasons set forth below, the motion for judgment n.o.v. will be granted.

Background

The evidence established that plaintiff was employed by Therakos’ parent, defendant Johnson & Johnson, at its corporate headquarters in the Office of Science and Technology from 1983 until December 1987. On January 1, 1988, plaintiff left Johnson & Johnson and became a full-time employee of Therakos, assuming the position of Vice President of Research and Development. Therakos contends that it hired plaintiff for a term of two years. Plaintiff contends that as events unfolded, Therakos’ commitment extended beyond two years.

Therakos had developed a photopheresis device (“UVAR”). UVAR was an instrument used to perform photopheresis, a therapeutic procedure that treats white blood cells extraeorporeally. At the time plaintiff joined Therakos, Therakos had submitted an application to the Food and Drug Administration (“FDA”) for permission to use its UVAR device known as photoceptor to treat Cutaneous T-Cell Lymphoma (“CTCL”). Therakos received FDA approval of photoceptor in March 1988 and began marketing it.

In January 1988, Therakos was seeking to develop an improved UVAR device, which it called Centrinet. It was also seeking to extend the use of photopheresis to the treatment of Scleroderma. Plaintiff was given major responsibility for this project. After plaintiff’s arrival at Therakos, differences developed between him and Therakos’ president, John MacLean. MaeLean became increasingly dissatisfied with plaintiff’s performance. Plaintiff, on the other hand, was highly critical of the manner in which Therakos was conducting efficacy testing of the new Centrinet.

Plaintiff contended that the photoceptor, which had been approved by the FDA, and the Centrinet were sufficiently different in structure and operation that, under FDA regulations, new clinical tests would be re *235 quired to establish Centrinet’s efficacy. Such tests would have delayed marketing Centrinet. Plaintiff advised MacLean and others of these views and he also advised MacLean that Therakos had to conduct additional testing to determine why in certain in vitro tests the same results had been reached using ultraviolet light only and using ultraviolet light and the drug 8-MOP — a result which, he contended, might cast doubts on submissions which Therakos had already made and planned to make to the FDA.

According to plaintiff, he repeatedly raised with MacLean his concerns about these and other areas in which Therakos had not performed and was not planning to perform research, and his concerns that what Therakos planned to do was in violation of FDA regulations. Plaintiff sought to establish that he was correct in his views and that his July 24, 1989 employment termination was because of his justifiable criticisms of the Centrinet approval plans. This, plaintiff contended, violated an agreement which Therakos had made with its employees in its Credo. The Credo is a widely-disseminated document applicable to Johnson & Johnson and all its affiliated companies, including Therakos. It sets forth these companies’ general obligations to (i) doctors, nurses patients, customers, suppliers and distributors, (ii) employees, (iii) the communities in which the companies operate, and (iv) stockholders.

The Credo provisions relating to employees read as follows:

We are responsible to our employees, the men and women who work with us throughout the world. Everyone must be considered as an individual. We must respect their dignity and recognize their merit. They must have a sense of security in their jobs. Compensation must be fair and. adequate, and working conditions clean, orderly and safe. Employees must feel free to make suggestions and complaints. There must be equal opportunity for employment, development and advancement for those qualified. We must provide competent management, and their actions must be just and ethical.

In particular, plaintiff relied on the Credo provisions that “[employees] must have a sense of security in their jobs,” “[e]mployees must feel free to make suggestions and complaints,” and “[management’s] actions must be just and ethical.”

It was Therakos’ position that MacLean and others listened to plaintiffs criticisms of the Centrinet testing procedures and proposed FDA submissions and concluded on the basis of opinions of highly qualified people on its own staff and the expert advice of scientists at Yale University that plaintiff was wrong in his opinions and that Therakos could properly rely on the tests which formed the basis for FDA approval of the photoceptor, supplemented by the additional tests which it had proposed.

Therakos contended that it terminated plaintiffs employment for a number of reasons, none of which had anything to do with the testing procedures and the FDA applications. Therakos contended that its reasons included plaintiffs failure to establish a time chart for completion of the engineering of the Centrinet, his failure to meet the goals for completing the various stages of the Centrinet project, inappropriate comments about Therakos’ top management, and his failure to guide the research effort at Yale University.

During the trial, each party presented extensive evidence directed to all the factual issues implicated in the parties’ contentions.

I presented plaintiffs Woolley claim to the jury. I instructed the jury that it first had to determine whether plaintiff and Therakos had agreed to a two-year term of employment or for an indefinite term, informing the jury that plaintiff would have no claim if his employment were for a fixed two-year period.

If the jury found that plaintiffs employment was for an indefinite term, the principles set forth in Woolley v. Hoffmann-LaRoche, Inc., 99 N.J. 284, 491 A.2d 1257 (1985) became applicable, and I charged the jury in accordance with those principles. The jury responded to the interrogatories as follows:

*236 1. Was the employment of the plaintiff by Therakos, Inc. for a two year term or for an indefinite term?
_ X TWO YEAR INDEFINITE TERM TERM
[If your answer to this question is “Two Year Term,” you should deliberate no further and should advise the court that you have reached a verdict.]
2.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

MURRAY v. COUNTY OF HUDSON
D. New Jersey, 2023
Costa v. Verizon New Jersey, Inc.
936 F. Supp. 2d 455 (D. New Jersey, 2013)
Younker v. Eastern Associated Coal Corp.
591 S.E.2d 254 (West Virginia Supreme Court, 2003)
Paul v. Hearst Corp.
261 F. Supp. 2d 303 (M.D. Pennsylvania, 2002)
Lithuanian Commerce Corp. v. Sara Lee Hosiery
219 F. Supp. 2d 600 (D. New Jersey, 2002)
Flizack v. Good News Home for Women, Inc.
787 A.2d 228 (New Jersey Superior Court App Division, 2001)
Monroe v. Host Marriot Services Corp.
999 F. Supp. 599 (D. New Jersey, 1998)
Kapossy v. McGraw-Hill, Inc.
921 F. Supp. 234 (D. New Jersey, 1996)
Allen v. Ethicon, Inc.
919 F. Supp. 1093 (S.D. Ohio, 1996)
King v. Port Authority of New York and New Jersey
909 F. Supp. 938 (D. New Jersey, 1995)

Cite This Page — Counsel Stack

Bluebook (online)
877 F. Supp. 233, 1995 U.S. Dist. LEXIS 1959, 1995 WL 75307, Counsel Stack Legal Research, https://law.counselstack.com/opinion/tripodi-v-johnson-johnson-njd-1995.